These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 38149013)
21. Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models. Le HN; Tran VG; Vu TTT; Gras E; Le VTM; Pinheiro MG; Aguiar-Alves F; Schneider-Smith E; Carter HC; Sellman BR; Stover CK; DiGiandomenico A; Diep BA Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160288 [No Abstract] [Full Text] [Related]
22. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics. Navas D; Caillon J; Gras-Le Guen C; Jacqueline C; Kergueris MF; Bugnon D; Potel G J Antimicrob Chemother; 2004 Oct; 54(4):767-71. PubMed ID: 15317741 [TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model. Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012 [TBL] [Abstract][Full Text] [Related]
25. Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model. Attwood M; Griffin P; Noel AR; Albur M; Macgowan AP J Antimicrob Chemother; 2023 Sep; 78(9):2254-2262. PubMed ID: 37527369 [TBL] [Abstract][Full Text] [Related]
26. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762 [TBL] [Abstract][Full Text] [Related]
27. Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes. Buyck JM; Tulkens PM; Van Bambeke F Antimicrob Agents Chemother; 2015 Jan; 59(1):258-68. PubMed ID: 25348528 [TBL] [Abstract][Full Text] [Related]
28. Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance. Petraitis V; Petraitiene R; Naing E; Aung T; Thi WP; Kavaliauskas P; Win Maung BB; Michel AO; Ricart Arbona RJ; DeRyke AC; Culshaw DL; Nicolau DP; Satlin MJ; Walsh TJ Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235620 [TBL] [Abstract][Full Text] [Related]
29. [Chinese expert consensus on the management of lower respiratory tract infections of Pulmonary Infection Assembly of Chinese Thoracic Society Zhonghua Jie He He Hu Xi Za Zhi; 2022 Aug; 45(8):739-752. PubMed ID: 35927044 [TBL] [Abstract][Full Text] [Related]
30. Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms. Haagensen J; Verotta D; Huang L; Engel J; Spormann AM; Yang K J Antimicrob Chemother; 2017 Dec; 72(12):3357-3365. PubMed ID: 28961810 [TBL] [Abstract][Full Text] [Related]
31. Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling. Bilal H; Tait JR; Lang Y; Zhou J; Bergen PJ; Peleg AY; Bulitta JB; Oliver A; Nation RL; Landersdorfer CB Antimicrob Agents Chemother; 2022 Mar; 66(3):e0220321. PubMed ID: 35041509 [TBL] [Abstract][Full Text] [Related]
36. Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study. Li Bassi G; Motos A; Fernandez-Barat L; Aguilera Xiol E; Chiurazzi C; Senussi T; Saco MA; Fuster C; Carbonara M; Bobi J; Amaro R; De Rosa F; Comaru T; Yang H; Ranzani OT; Marti JD; Rinaudo M; Comino Trinidad O; Rigol M; Bringué J; Ramirez J; Nicolau DP; Pelosi P; Antonelli M; Blasi F; Artigas A; Montgomery AB; Torres A Crit Care Med; 2019 Jun; 47(6):e470-e477. PubMed ID: 30882478 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of meropenem extended infusion vs intermittent bolus monotherapy and in combination with colistin against Pseudomonas aeruginosa biofilm. Benavent E; Ulldemolins M; El Haj C; Rigo-Bonnin R; Yu H; Wang L; Wickremasinghe H; Ariza J; Murillo O Int J Antimicrob Agents; 2023 Aug; 62(2):106856. PubMed ID: 37211260 [TBL] [Abstract][Full Text] [Related]
38. MEDI3902 Correlates of Protection against Severe Pseudomonas aeruginosa Pneumonia in a Rabbit Acute Pneumonia Model. Le HN; Quetz JS; Tran VG; Le VTM; Aguiar-Alves F; Pinheiro MG; Cheng L; Yu L; Sellman BR; Stover CK; DiGiandomenico A; Diep BA Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483116 [No Abstract] [Full Text] [Related]
39. Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations. Motos A; Avery LM; DeRonde KJ; Mullane EM; Kuti JL; Nicolau DP Int J Antimicrob Agents; 2019 May; 53(5):698-702. PubMed ID: 30880231 [TBL] [Abstract][Full Text] [Related]
40. Comparative activities of N-formimidoyl thienamycin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. Pennington JE; Johnson CE Antimicrob Agents Chemother; 1982 Sep; 22(3):406-8. PubMed ID: 6814354 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]